open access

Vol 12, No 1 (2016)
Review paper
Published online: 2016-04-29
Get Citation

Breakthrough pain in cancer patients

Kinga Winiarczyk, Magdalena Knetki-Wróblewska
Oncol Clin Pract 2016;12(1):1-7.

open access

Vol 12, No 1 (2016)
REVIEW ARTICLES
Published online: 2016-04-29

Abstract

Breakthrough pain is a brief episode of severe pain occurring in patients undergoing analgesic procedures in the course of cancer. It affects about 70% of patients and significantly influences their quality of life. It is important to identify specific types of pain and inducing factors. Treatment is based on modification of pain management including use of immediate-release drug formulations.

Abstract

Breakthrough pain is a brief episode of severe pain occurring in patients undergoing analgesic procedures in the course of cancer. It affects about 70% of patients and significantly influences their quality of life. It is important to identify specific types of pain and inducing factors. Treatment is based on modification of pain management including use of immediate-release drug formulations.

Get Citation

Keywords

breakthrough pain; cancer; fentanyl

About this article
Title

Breakthrough pain in cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 1 (2016)

Article type

Review paper

Pages

1-7

Published online

2016-04-29

Bibliographic record

Oncol Clin Pract 2016;12(1):1-7.

Keywords

breakthrough pain
cancer
fentanyl

Authors

Kinga Winiarczyk
Magdalena Knetki-Wróblewska

References (33)
  1. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002; 24(1): 45–52.
  2. Lesage P, Portenoy RK. Trends in Cancer Pain Management Cancer. 2009.
  3. Control. 1999; 6: 136–145.
  4. Twycross RG, Fairfield S. Pain in far-advanced cancer. Pain. 1982; 14(3): 303–310.
  5. Vuorinen E. Pain as an early symptom in cancer. Clin J Pain. 1993; 9(4): 272–278.
  6. World Health Organization. Cancer pain relief: with a guide to opioid availability. 2 ed Geneva, 1996.
  7. Portenoy R, Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41(3): 273–281.
  8. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999; 82(3): 263–274.
  9. Vellucci R, Fanelli G, Pannuti R, et al. What to do, and what not to do, when diagnosis and treating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016; 11: 1–16.
  10. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999; 79(2-3): 303–312.
  11. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998; 16(10): 3238–3245.
  12. Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. Eur J Pain. 2013; 17(2): 264–270.
  13. Webber K, Davies AN, Zeppetella G, et al. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014; 48(4): 619–631.
  14. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013; 46(5): 619–628.
  15. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999; 81(1-2): 129–134.
  16. Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995; 10(5): 348–355.
  17. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003; 101(1-2): 55–64.
  18. Bennett D, Burton A, Fishman S, et al. Consensus Panel Recomendation for the assessment and management of breathrough pain. Part 2 . Management P&T. 2005: 354–361.
  19. Hilgier M. Bóle przebijające w chorobie nowotworowej. Współczesna Onkologia. 2001; 5: 168–174.
  20. Zeppetella G. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care (Engl). 2009; 18(4): 331–337.
  21. McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007; 8 Suppl 1: 8–13.
  22. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001; 91(1-2): 123–130.
  23. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006; 22(9): 805–811.
  24. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30(3): 469–481.
  25. Kress HG, Orońska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009; 31(6): 1177–1191.
  26. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009; 25(11): 2805–2815.
  27. Davies A, Bagg J, Laverty D, et al. Salivary gland dysfunction ('dry mouth') in patients with cancer: a consensus statement. Eur J Cancer Care (Engl). 2010; 19(2): 172–177.
  28. Nave R, Sides EH, Colberg T, et al. Pharmacokintetics of intranasal fentanyl spray (INFS) in subjects with common cold. Abstr IASP. 2009.
  29. Nave R, Sides EH, Colberg T, et al. Pharmacokintetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior admininstartion of oxymetazoline. Abstr IASP. 2009.
  30. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007; 5(7): 327–334.
  31. Zeppetella G, Davies A, Eijgelshoven I, et al. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014; 47(4): 772–785.
  32. Ripamonti CI, Santini D, Maranzano E, et al. ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7: vii139–vii154.
  33. Jarosz J, Kaczmarek Z, Kowalski DM. Postępowanie w bólach nowotworowych. W: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 r. Via Medica, Gdańsk 2013: 625–637.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl